ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO0247

SLC4A1 (Anion Exchanger 1/ AE1) Variants as a Rare Cause of Distal Renal Tubular Acidosis (dRTA) and Recurrent Nephrolithiasis

Session Information

Category: Bone and Mineral Metabolism

  • 502 Bone and Mineral Metabolism: Clinical

Authors

  • Fichadiya, Harshil, Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Lieske, John C., Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Erickson, Stephen B., Mayo Clinic Minnesota, Rochester, Minnesota, United States
Introduction

Patients with dRTA variably manifest basic urine pH, CaP nephrolithiasis, hypokalemia, NAGMA, hypercalciuria and bone disease. Causes include autoimmune disease(Sjogren disease), use of carbonic anhydrase inhibitors (especially topiramate) and pathologic genetic variants including ATP6V1B1 and SLC4A1 that mediate distal renal acidification

Case Description

We recently completed targeted gene panel testing in 2 patients that presented to the Mayo Nephrology Clinic with a history of Ca-P and meduallry nephrocalcinosis. Key fingings are detailed in Table 1. Both had clinical evidence for dRTA with high 24 hr urine pH and low urinary citrate. However, there were other subtle differences between the 2 including age of onset, degree of nephrocalcinosis, and the presence of concurrent RBC morphologic changes.

Discussion

SLC4A1 encodes AE1 which responsible for bicarbonate (HCO3) and chloride (Cl) exchange on the surface of cirulating RBCs and the basolateral surface of alpha-intercalated cells in the kidney. Genetic variation in SLC4A1 is a rare but reported cause of dRTA, and depending on the variant and resulting defect (mislocalization or loss of function) inheritance may be biallelic or monoallelic. Treatment with alkali (including citrate)may reduce hypercalciuria, and improve urine citrate and reduce systemic acoidosis (if present), which maybe particularly important for bone health. However, the net effect on stones and nephrocalcnosis of any increase in urine pH has not been established with some theoretic concern that in overly alkaline urine may promote Ca-P crystallization. Further identification of cases in order to develop cohorts to study the natural history of this disease and understand genotype phenotype correlations is sorely needed.

Digital Object Identifier (DOI)